Page 1 - CUA Adv Prostate Ca Drug Access List-MAR-2022

Drug Access Listing: Advanced Prostate Cancer

Oral agents and Outpatient Injections

Click on province or patient assistance programs. The information in this document is intended for healthcare
professionals experienced in the treatment of prostate cancer.

The drug funding descriptions found within are based on
information acquired from pharmaceutical manufacturers and
internet resources. Please report any gaps, outdated
information, or inaccuracies to the CUA so that appropriate
revisions can be made with future updates.

BC

AB NL
PEI

SK
MB QC
ON NS
NB

Patient Assistance Programs

ADT, androgen deprivation therapy; ALT, alanine transaminase; ARAT, androgen receptor – axis targeted therapy; ARI, androgen receptor inhibitor (second-generation); AST, aspartate transaminase;
CAROC, Canadian Association of Radiologists and Osteoporosis Canada; CRPC, castration-resistance prostate cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FRAX,
World Health Organization’s Fracture Risk Assessment; HRR, homologous recombination repair; LVEF, left ventricular ejection fraction; mCRPC, metastatic castration-resistance prostate cancer;
nmCRPC, non-metastatic castration-resistance prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time;
SRE, skeletal related event; ULN, upper limit of normal.

Page 1 | © Canadian Urological Association
v.01-MAR-2022